Gilead Sciences

91,928

$74.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.90 (-1.19%) Today
-$0.15 (-0.20%) As of 7:54 PM EDT after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
93.71B
Price-Earnings Ratio
19.64
Dividend Yield
3.43
Average Volume
8.34M
High Today
$75.84
Low Today
$73.95
Open Price
$75.24
Volume
5.20M
52 Week High
$85.97
52 Week Low
$60.89

Collections

GILD News

Reuters16h

Gilead to deliver more remdesivir to Europe from autumn: WiWo

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients
0
ReutersJul 8

BRIEF-Gilead Sciences Announces Initiation Of Phase 1A Clinical Study To Evaluate Investigational, Inhaled Solution Of Remdesivir In Healthy Volunteers

July 8 (Reuters) - Gilead Sciences Inc: * GILEAD SCIENCES INC - STATEMENT ON INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL
0
ReutersJul 8

Gilead begins testing inhalable form of remdisivir for COVID-19

July 8 (Reuters) - Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled,
0

GILD Earnings

$0.00
$0.61
$1.21
$1.82
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Expected Jul 30, After Hours

You May Also Like

More GILD News

MarketWatchJul 8

Gilead's stock drops as it starts early-stage trial for inhaled remdesivir

Shares of Gilead Sciences Inc. GILD, -1.41% fell 1.4% in trading on Wednesday after the drugmaker said it started a Phase 1a clinical study testing an inhaled v
0
ReutersJul 7

India's Sovereign Pharma dispatches first batch of remdesivir to Cipla

BENGALURU (Reuters) - India’s Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded mor
0
ReutersJul 6

UPDATE 1-Germany has only a few hundred remdesivir doses - minister

(Adds quotes, background) BRUSSELS, July 6 (Reuters) - Germany has only a few hundred doses of COVID-19 antiviral remdesivir, health minister Jens Spahn told E
0
ReutersJul 6

Mylan to launch generic remdesivir version in India at $64 per 100 mg vial

FILE PHOTO: An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg BENGALURU (Reuters) - Drugmaker
0
ReutersJul 6

BRIEF-Precision BioSciences Says Will Regain Full Rights, All Data It Generated For HBV Program Developed Under Agreement With Gilead Sciences

July 6 (Reuters) - Precision BioSciences Inc: * PRECISION BIOSCIENCES REGAINS RIGHTS TO IN VIVO HEPATITIS B VIRUS PROGRAM * PRECISION BIOSCIENCES - WILL REGAI
0
ReutersJul 4

BRIEF-Gilead Sciences New Findings On Gilead's Biktarvy Presented At AIDS 2020

July 4 (Reuters) - Gilead Sciences Inc: * NEW FINDINGS ON GILEAD’S BIKTARVY PRESENTED AT AIDS 2020, VIRTUAL INCLUDE POSITIVE SWITCH DATA IN OLDER ADULTS * GIL
0
ReutersJul 4

BRIEF-Gilead Presents Data Supporting Potential Six-Month Dosing Interval For Investigational HIV-1 Capsid Inhibitor Lenacapavir

July 4 (Reuters) - Gilead Sciences Inc: * GILEAD SCIENCES PRESENTS DATA SUPPORTING A POTENTIAL SIX-MONTH DOSING INTERVAL FOR INVESTIGATIONAL HIV-1 CAPSID INHIB
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.